Rosalind Hollingsworth, PhD
Global Medical Franchise Head for Influenza/RSV, Sanofi Pasteur, Swiftwater, Pennsylvania, USA
Since completing her undergraduate, doctoral, and post-doctoral studies at the University of Nottingham in the United Kingdom, Rosalind has spent nearly 20 years’ in vaccines medical affairs and clinical research within the pharmaceutical industry. Rosalind joined Sanofi Pasteur in March 2015. She is currently Global Medical Franchise Head for Influenza/RSV, working with her team to develop and execute the global medical strategy for Sanofi Pasteur's licensed influenza vaccines and support pipeline research and development projects, with the recent addition of developmental vaccines for the prevention of COVID-19 disease. Prior to joining Sanofi Pasteur, Rosalind spent 14 years in Global Medical Affairs at Pfizer with responsibility for pneumococcal conjugate vaccines. Rosalind has also worked with group C meningococcal conjugate vaccines, live attenuated influenza vaccine, transcutaneous vaccine delivery and, beyond vaccines, antibiotics (tigecycline and piperacillin-tazobactam). Rosalind’s early research focused on an evaluation of host and viral factors which could influence the rate of progression and clinical outcome of hepatitis C virus infection, with post-doctoral research on early vaccine candidates for the prevention of group B meningococcal disease.